These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38160212)

  • 1. Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Sánchez-Castillo A; Heylen E; Hounjet J; Savelkouls KG; Lieuwes NG; Biemans R; Dubois LJ; Reynders K; Rouschop KM; Vaes RDW; De Keersmaecker K; Lambrecht M; Hendriks LEL; De Ruysscher DKM; Vooijs M; Kampen KR
    Br J Cancer; 2024 Mar; 130(4):568-584. PubMed ID: 38160212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis-Addicted Breast Tumor Growth.
    Geeraerts SL; Kampen KR; Rinaldi G; Gupta P; Planque M; Louros N; Heylen E; De Cremer K; De Brucker K; Vereecke S; Verbelen B; Vermeersch P; Schymkowitz J; Rousseau F; Cassiman D; Fendt SM; Voet A; Cammue BPA; Thevissen K; De Keersmaecker K
    Mol Cancer Ther; 2021 Jan; 20(1):50-63. PubMed ID: 33203732
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Fan TWM; Bruntz RC; Yang Y; Song H; Chernyavskaya Y; Deng P; Zhang Y; Shah PP; Beverly LJ; Qi Z; Mahan AL; Higashi RM; Dang CV; Lane AN
    J Biol Chem; 2019 Sep; 294(36):13464-13477. PubMed ID: 31337706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.
    Zhang X; Cheung RM; Komaki R; Fang B; Chang JY
    Clin Cancer Res; 2005 Sep; 11(18):6657-68. PubMed ID: 16166445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
    Biziotis OD; Tsakiridis EE; Ali A; Ahmadi E; Wu J; Wang S; Mekhaeil B; Singh K; Menjolian G; Farrell T; Abdulkarim B; Sur RK; Mesci A; Ellis P; Berg T; Bramson JL; Muti P; Steinberg GR; Tsakiridis T
    Mol Oncol; 2023 Nov; 17(11):2235-2256. PubMed ID: 37584455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
    Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
    Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy.
    Jiang X; Lu W; Shen X; Wang Q; Lv J; Liu M; Cheng F; Zhao Z; Pang X
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer.
    Yu D; Yang P; Lu X; Huang S; Liu L; Fan X
    Cell Commun Signal; 2023 Jul; 21(1):169. PubMed ID: 37430270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.
    van den Heuvel MM; Verheij M; Boshuizen R; Belderbos J; Dingemans AM; De Ruysscher D; Laurent J; Tighe R; Haanen J; Quaratino S
    J Transl Med; 2015 Jan; 13():32. PubMed ID: 25622640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-181a reduces radiosensitivity of non-small-cell lung cancer via inhibiting PTEN.
    Chen Y; Liao W; Yuan A; Xu H; Yuan R; Cao J
    Panminerva Med; 2022 Sep; 64(3):374-383. PubMed ID: 32506887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
    Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response.
    Kuo P; Bratman SV; Shultz DB; von Eyben R; Chan C; Wang Z; Say C; Gupta A; Loo BW; Giaccia AJ; Koong AC; Diehn M; Le QT
    Clin Cancer Res; 2014 Nov; 20(21):5558-69. PubMed ID: 25189484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
    Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
    J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
    Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
    IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
    Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
    Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
    Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
    J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.
    Storozhuk Y; Hopmans SN; Sanli T; Barron C; Tsiani E; Cutz JC; Pond G; Wright J; Singh G; Tsakiridis T
    Br J Cancer; 2013 May; 108(10):2021-32. PubMed ID: 23632475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.